Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
1.43B
Enterprise Value
960.22M
Income
-32.09M
Sales
429.13M
Book/sh
8.08
Cash/sh
17.45
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
524
IPO
Feb 05, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
3.32
P/B
3.42
P/C
1.58
P/FCF
-
EV/EBITDA
-
EV/Sales
2.24
Quick Ratio
4.59
Current Ratio
4.62
Debt/Eq
1.04
LT Debt/Eq
1.03
Option/Short
Yes / Yes
EPS (ttm)
-0.62
EPS next Y
-0.48
EPS next Q
-0.20
EPS this Y
67.35%
EPS next Y
-105.93%
EPS next 5Y
23.59%
EPS past 3/5Y
- -
Sales past 3/5Y
31.32% 59.68%
EPS Y/Y TTM
-
Sales Y/Y TTM
13.01%
EPS Q/Q
-7777.14%
Sales Q/Q
-0.85%
Insider Own
0.96%
Insider Trans
0.00%
Inst Own
97.67%
Inst Trans
-3.87%
ROA
-2.88%
ROE
-7.86%
ROIC
-3.76%
Gross Margin
97.95%
Oper. Margin
-6.76%
Profit Margin
-7.48%
SMA20
-9.42%
SMA50
-9.87%
SMA200
-12.39%
Trades
Shs Outstand
51.64M
Shs Float
51.14M
52W High
40.71 -32.19%
52W Low
27.31 1.10%
Volatility
5.21% 5.13%
ATR (14)
1.42
RSI (14)
36.93
Beta
0.83
Rel Volume
0.51
Avg Volume
459.28K
Volume
182,875
Perf Week
-12.76%
Perf Month
-15.31%
Perf Quarter
-23.90%
Perf Half Y
-6.53%
Perf YTD
-20.46%
Perf Year
-27.46%
Perf 3Y
-41.18%
Perf 5Y
-28.12%
Perf 10Y
-
Prev Close
27.81
Price
27.61
Change %
-0.72%
Consensus
Buy
Avg. Price Target
$61.18
Implied Upside
+121.6%
Analysts14incl. previous ratings
Rating Distribution9 Buy · 5 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 21, 2026Resumed
JPM logoJJP Morgan
Overweight$50+81.1%
Mar 16, 2026Downgrade
JEF logoJJefferies
Buy → Hold$33+19.5%
Jan 07, 2026Upgrade
UBS logoUUBS
Sell → Buy$55+99.2%
Oct 31, 2025Initiated
WFC logoWWells Fargo
Overweight$60+117.3%
Sep 18, 2025Resumed
GGuggenheim
Neutral
Aug 25, 2025Resumed
JEF logoJJefferies
Buy$48+73.9%
May 27, 2025Initiated
DB logoDDeutsche Bank
Buy$65+135.4%
Dec 13, 2024Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$74 → $35+26.8%
Nov 11, 2024Downgrade
MFG logoMMizuho
Outperform → Neutral$72 → $38+37.6%
Oct 24, 2024Initiated
UBS logoUUBS
Sell$24-13.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
David BermanAffiliateMay 22 '26Proposed Sale29.4869,2712,042,148May 22 03:44 PM
David BermanAffiliateMay 21 '26Proposed Sale29.1565,0001,894,638May 21 01:56 PM
David BermanAffiliateApr 08 '26Proposed Sale31.8525,000796,250Apr 08 03:57 PM
David BermanaffiliateMar 11 '26Proposed Sale32.5711,832385,330Mar 11 01:47 PM
Jallal BahijaCHIEF EXECUTIVE OFFICERFeb 17 '26Option Exercise0.0023,817023,817Feb 19 05:00 PM
Jallal BahijaCHIEF EXECUTIVE OFFICERFeb 18 '26Sale32.3511,474371,18412,343Feb 19 05:00 PM
GOLL JOHNSVP, FINANCE & CAOFeb 17 '26Option Exercise0.001,35101,351Feb 19 05:00 PM
GOLL JOHNSVP, FINANCE & CAOFeb 18 '26Sale32.3569822,580653Feb 19 05:00 PM
St Leger Tina AmberCHIEF HR OFFICERFeb 17 '26Option Exercise0.002,11902,119Feb 19 05:00 PM
St Leger Tina AmberCHIEF HR OFFICERFeb 18 '26Sale32.351,00032,3501,119Feb 19 05:00 PM
Berman David MHEAD OF R&DFeb 17 '26Option Exercise0.0011,824011,824Feb 19 05:00 PM
Berman David MHEAD OF R&DFeb 18 '26Sale32.355,965192,9685,859Feb 19 05:00 PM
David BermanaffiliateFeb 18 '26Proposed Sale32.355,965192,951Feb 18 04:22 PM
Tina St LegeraffiliateFeb 18 '26Proposed Sale32.351,00032,347Feb 18 04:19 PM
Bahija JallalaffiliateFeb 18 '26Proposed Sale32.3511,474371,152Feb 18 04:18 PM
Berman David MHEAD OF R&DDec 04 '25Option Exercise17.4631,341547,21431,341Dec 08 04:15 PM
Berman David MHEAD OF R&DDec 05 '25Option Exercise17.465729,987572Dec 08 04:15 PM
Berman David MHEAD OF R&DDec 04 '25Sale40.2631,3411,261,7890Dec 08 04:15 PM
Berman David MHEAD OF R&DDec 05 '25Sale40.1457222,9600Dec 08 04:15 PM
Berman David MHEAD OF R&DNov 26 '25Option Exercise17.4669,4041,211,79469,404Dec 01 04:10 PM
Berman David MHEAD OF R&DNov 28 '25Option Exercise17.465,52196,3975,521Dec 01 04:10 PM
Berman David MHEAD OF R&DNov 26 '25Sale40.1269,4042,784,4880Dec 01 04:10 PM
Berman David MHEAD OF R&DNov 28 '25Sale40.095,521221,3370Dec 01 04:10 PM
Berman David MHEAD OF R&DNov 25 '25Option Exercise17.4618,020314,62918,020Nov 26 04:10 PM
Berman David MHEAD OF R&DNov 24 '25Option Exercise17.461001,746100Nov 26 04:10 PM
Berman David MHEAD OF R&DNov 25 '25Sale40.0318,020721,3410Nov 26 04:10 PM
Berman David MHEAD OF R&DNov 24 '25Sale40.001004,0000Nov 26 04:10 PM
David M. BermanOfficerNov 24 '25Proposed Sale39.35136,7905,382,687Nov 24 04:56 PM
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
CEO & Executive DirectorDr. Bahija Jallal Ph.D.
CFOMr. Travis Alan Coy M.B.A.
Executive VP & Chief Operating OfficerDr. Kripa Ram Ph.D.
SVPMr. John Goll III
Chief Science and Technology Officer & Milton Park Site HeadMs. Annelise Vuidepot Ph.D.